Search | OpenScholar

Search results

374 results found

Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson’s disease.

Publication: Journal Article

Hauser, RA, L Salin, N Juhel, and VL Konyago. 2007. “Randomized Trial of the Triple Monoamine Reuptake Inhibitor NS 2330 (tesofensine) in Early Parkinson’s Disease.”. Movement Disorders.

Initial management of Parkinson’s disease in a Florida community. J Applied Research 2004;4:95-98.

Publication: Journal Article

Zesiewicz, TA, SN Carter, KL Sullivan, JS Staffetti, PB Dunne, and RA Hauser. 2004. “Initial Management of Parkinson’s Disease in a Florida Community. J Applied Research 2004;4:95-98.”. J Applied Research.

Substantial improvement in a Meige's syndrome patient with levetiracetam treatment. Movement Disorders 2004;19:1518-1521.

Publication: Journal Article

Zesiewicz, TA, ED Louis, KL Sullivan, M Menkin, PB Dunne, and RA Hauser. 2004. “Substantial Improvement in a Meige’s Syndrome Patient With Levetiracetam Treatment. Movement Disorders 2004;19:1518-1521.”. Movement Disorders.

Essential tremor. Epidemiology, diagnosis, and treatment. Neurologist 2004;10:250-258.

Publication: Journal Article

Sullivan, KL, RA Hauser, and TA Zesiewicz. 2004. “Essential Tremor. Epidemiology, Diagnosis, and Treatment. Neurologist 2004;10:250-258.”. Neurologist.

Double-blinded, placebo-controlled study of entacapone in levodopa-treated patients with Parkinson disease. Archives of neurology, 61(10), 1563.

Publication: Journal Article

Olanow, CW, K Kieburtz, M Stern, R Watts, JW Langston, M Guarnieri, RA Hauser, and J Hubble. 2004. “Double-Blinded, Placebo-Controlled Study of Entacapone in Levodopa-Treated Patients With Parkinson Disease. Archives of Neurology, 61(10), 1563.”. Archives of Neurology.

Autonomic nervous system dysfunction in Parkinson’s disease. Curr Treat Options Neurol 2003; 5:149-160.

Publication: Journal Article

Zesiewicz, TA, MJ Baker, M Wahba, and RA Hauser. 2003. “Autonomic Nervous System Dysfunction in Parkinson’s Disease. Curr Treat Options Neurol 2003; 5:149-160.”. Curr Treat Options Neurol.

Progress in pursuit of therapeutic A2A antagonists: the adenosine A2A receptor selective antagonist KW6002: research and development toward a novel nondopaminergic therapy for Parkinson’s disease.

Publication: Journal Article

Kase, H, S Aoyama, M Ichimura, K Ikeda, A Ishii, T Kanda, K Koga, and . 2003. “Progress in Pursuit of Therapeutic A2A Antagonists: the Adenosine A2A Receptor Selective Antagonist KW6002: Research and Development Toward a Novel Nondopaminergic Therapy for Parkinson’s Disease.”. Neurology.

Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD. Neurology 2003;61:297-303.

Publication: Journal Article

Hauser, RA, JP Hubble, and DD Truong. 2003. “Randomized Trial of the Adenosine A2A Receptor Antagonist Istradefylline in Advanced PD. Neurology 2003;61:297-303.”. Neurology.

Driving safety in Parkinson’s disease. Neurology 2002;59:1787-1788.

Publication: Journal Article

Zesiewicz, TA, CR Cimino, AR Malek, N Gardner, PL Leaverton, PB Dunne, and RA Hauser. 2002. “Driving Safety in Parkinson’s Disease. Neurology 2002;59:1787-1788.”. Neurology.

Cyclosporine-A increases locomotor activity in rats with 6-hydroxydopamine-induced hemiparkinsonism: relevance to neural transplantation. Surgical Neurology 1996;46:384-388.

Publication: Journal Article

Borlongan, CV, TB Freeman, RA Hauser, DW Cahill, and PR Sanberg. 1996. “Cyclosporine-A Increases Locomotor Activity in Rats With 6-Hydroxydopamine-Induced Hemiparkinsonism: Relevance to Neural Transplantation. Surgical Neurology 1996;46:384-388.”. Surgical Neurology.